• Tomivosertib Suppresses Human DRG Neuron Hyperactivity in Ra

  2026-07-08

  The reference study delivers the first direct evidence that MNK inhibition via tomivosertib rapidly and reversibly suppresses spontaneous hyperactivity in human dorsal root ganglion neurons from radiculopathy patients. These findings establish a mechanistic link between MNK signaling and neuropathic pain, supporting the translational potential of MNK inhibitors in pain therapeutics.

• SCH772984 HCl: Advanced Insights into ERK1/2 Inhibition and

  2026-07-08

  Explore the advanced mechanisms and translational applications of SCH772984 HCl, a potent ERK1/2 inhibitor, with unique insights into spatially regulated protein synthesis. This article delivers a scientific bridge from cancer to cardiac biology, offering depth beyond standard MAPK pathway inhibitor content.

• BV6 IAP Antagonist: Deep Mechanistic Insights and Translatio

  2026-07-07

  Explore how BV6, a selective IAP antagonist, enables precise apoptosis induction in cancer cells and advances translational research. This article delivers an in-depth analysis of BV6's mechanisms, supported by the latest cell death pathway discoveries.

• Methoxy-X04: Fluorescent Amyloid Beta Probe in AD Research

  2026-07-07

  Methoxy-X04 delivers rapid, high-contrast amyloid beta imaging for Alzheimer's disease research, enabling visualization of both soluble oligomers and insoluble plaques in vivo. Its robust blood-brain barrier permeability and validated workflow compatibility accelerate translational breakthroughs from bench to bedside.

• Cabazitaxel (XRP6258): Technical Guidance for Resistant Mode

  2026-07-06

  Cabazitaxel (XRP6258) is a semi-synthetic taxane formulated to disrupt microtubule dynamics in cancer research models that exhibit resistance to conventional taxanes. It is specifically suited for use in DMSO- or ethanol-based workflows and should not be used in aqueous systems or stored in solution long term due to solubility and stability constraints.

• Low-Affinity N-Type Calcium Channel Blockade by v-Agatoxin-I

  2026-07-06

  Sidach and Mintz (2000) reveal that the spider toxin v-Agatoxin-IVA, traditionally regarded as a highly selective P-type calcium channel blocker, also exerts low-affinity inhibition of N-type channels in mammalian neurons. This nuanced pharmacological profile challenges canonical channel classification and has far-reaching implications for experimental design in neurophysiology and neuroprotective agent research.

• RSL3: A Precision Glutathione Peroxidase 4 Inhibitor for Fer

  2026-07-05

  (1S,3R)-RSL3 is a highly selective glutathione peroxidase 4 inhibitor that induces ferroptosis via lipid peroxidation. Its action enables robust, caspase-independent cell death in RAS-driven cancers, demonstrating synthetic lethality and translational potential in preclinical oncology research.

• Morin: Applied Protocols for Antioxidant and Ion Probe Resea

  2026-07-04

  Morin (2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one) bridges antioxidant and bioanalytical workflows with unique dual activity as a mitochondrial modulator and fluorescent aluminum ion probe. This guide delivers actionable, evidence-backed strategies for maximizing Morin’s performance in metabolic, neuroprotective, and metal detection assays.

• Parathyroid Hormone (1-34) (Human): Applied Workflows & Opti

  2026-07-03

  Parathyroid hormone (1-34) (human) empowers advanced bone and kidney disease modeling with reproducible, high-fidelity results. This guide demystifies workflow setup, protocol refinements, and troubleshooting, leveraging recent breakthroughs in spatially patterned kidney assembloids and APExBIO’s gold-standard peptide fragment.

• Pregnenolone Carbonitrile: Precision for CYP3A and Neuroprot

  2026-07-03

  Explore how Pregnenolone Carbonitrile (PCN) is redefining the frontiers of translational research by uniquely bridging hepatic detoxification and neuroprotective mechanisms. This article synthesizes mechanistic insight, experimental guidance, and practical perspectives for translational scientists striving to unravel the dual PXR- and glucocorticoid receptor-dependent actions of PCN. Strategic protocol recommendations, competitive landscape analysis, and a vision for the next decade of xenobiotic metabolism and antifibrotic research are presented, grounded in recent evidence and workflow-ready expertise.

• Methoxy-X04: High-Affinity Fluorescent Amyloid Beta Probe

  2026-07-02

  Methoxy-X04 is a brain-permeable, high-affinity fluorescent amyloid beta probe enabling rapid, selective visualization of amyloid pathology in Alzheimer's disease models. Its nanomolar binding to Aβ fibrils and capacity for in vivo plaque imaging underpin its value in neurodegenerative research and workflow reproducibility.

• SU 5402: Precision FGFR/VEGFR Inhibition and Human Neuron Mo

  2026-07-02

  Explore the multifaceted research utility of SU 5402, a potent receptor tyrosine kinase inhibitor. This article uniquely examines SU 5402’s mechanistic actions and its integration with advanced human sensory neuron models, providing new perspectives for multiple myeloma and neurovirology research.

• Applied Workflows with 2-(4,5,6,7-tetrabromo...) Acetic Acid

  2026-07-01

  2-(4,5,6,7-tetrabromo-2-(dimethylamino)-1H-benzo[d]imidazol-1-yl)acetic acid empowers researchers to dissect kinase-driven processes with precision, enabling both protein interaction studies and phase separation assays. This small molecule inhibitor, available from APExBIO, stands out for its dual targeting of CK2 and ERK8, reproducible DMSO solubility, and validated performance in translational enzymology.

• Bufalin Targets STK33 to Suppress Triple-Negative Breast Can

  2026-07-01

  The reference study uncovers Serine/Threonine Kinase 33 (STK33) as a direct and druggable target of Bufalin in triple-negative breast cancer (TNBC). By elucidating the detailed mechanism—Bufalin-induced degradation of STK33—the work advances our understanding of apoptosis induction and suggests a new therapeutic avenue for aggressive breast cancer subtypes.

• BMS 309403 in Atherosclerosis: Decoding FABP4 Inhibition Mec

  2026-06-30

  Explore how BMS 309403, a potent FABP4 inhibitor, uniquely advances atherosclerosis and type 2 diabetes research by dissecting the calcineurin/FoxO1/FABP4 pathway. This article provides technical clarity and practical insights not found in prior guides.

15369 records 1/1025 page Next 12345 下5页 Last page